Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Prasugrel Review Extended: Why No News May Be Good News

This article was originally published in The Pink Sheet Daily

Executive Summary

Platelet drug deadline slips, but analysis by The RPM Report suggests that may be a sign of a positive outcome.
Advertisement

Related Content

Cancer, Bleeding Risks At The Heart Of Prasugrel Review; Could Limiting Use Help?
Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3
FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
Ipsen’s Dysport Gets Complete Response Letter, Request For REMS
Prasugrel Delay Could Extend Well Into 2009; FDA Eyes February Cmte. Review
Lilly Prasugrel Delay Could Extend Well Into 2009
Pharma Thriller: Lilly Rumored To Be Mystery Bidder For ImClone
Pharma Thriller: ImClone’s Secret Suitor Remains Cloaked In Mystery
FDA Review Of Ipsen’s Dysport Set Back Three Months
Prasugrel Round Two: Is FDA Approval In Sight?

Topics

Advertisement
UsernamePublicRestriction

Register

PS068416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel